Cytomegalovirus News and Research

RSS
Cytomegalovirus (CMV) is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella-zoster virus (which causes chickenpox), and Epstein-Barr virus (which causes infectious mononucleosis). Infection with CMV is a major cause of disease and death in immunocompromised patients, including organ transplant recipients, patients undergoing hemodialysis, patients with cancer, patients receiving immunosuppressive drugs, and HIV-infected patients. While drugs are available for treatment of these conditions, the primary drug choices carry significant side effects and warnings. Currently, there are no anti-CMV drugs indicated for treatment of primary CMV infection during pregnancy resulting in infections that can have catastrophic consequences to the newborn. Maternal-fetal transfer of CMV infection results in a fetal death rate of 12% and most survivors have permanent debilitating disorders, including mental retardation, vision loss, and sensorineural deafness.

Further Reading

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

Detection of prior SARS-CoV-2 infection by T-cell receptor sequencing

Detection of prior SARS-CoV-2 infection by T-cell receptor sequencing

Nurseries, schools, nursing homes and other indoor settings exposed to high levels of respiratory pathogens during winter

Nurseries, schools, nursing homes and other indoor settings exposed to high levels of respiratory pathogens during winter

SARS-CoV-2 RBD is a selective integrin agonist

SARS-CoV-2 RBD is a selective integrin agonist

Experimental tool can precisely pick out interactions between immune cell and target antigen

Experimental tool can precisely pick out interactions between immune cell and target antigen

Air surveillance of SARS-CoV-2 and other respiratory pathogens

Air surveillance of SARS-CoV-2 and other respiratory pathogens

Furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases

Furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases

Algal metabolites as novel drugs against viruses

Algal metabolites as novel drugs against viruses

Breast milk components show potent in vitro SARS-CoV-2 inhibition

Breast milk components show potent in vitro SARS-CoV-2 inhibition

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Diabetes and the mTOR pathway in COVID-19 patients

Diabetes and the mTOR pathway in COVID-19 patients

Study proposes SARS-CoV-2-encoded peptide presented by HLA-E may suppress inhibition of natural killer cells

Study proposes SARS-CoV-2-encoded peptide presented by HLA-E may suppress inhibition of natural killer cells

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Study opens the door to a new approach to attacking herpesviruses

Study opens the door to a new approach to attacking herpesviruses

Providing recombinant antibody services and more within Europe

Providing recombinant antibody services and more within Europe

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Transplant recipients benefit from a COVID-19 vaccine booster

Transplant recipients benefit from a COVID-19 vaccine booster

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.